Finance News – Glp
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
GMX finalizes $44 million plan to compensate GLP holders affected by recent hack
GMX has announced a $44 million compensation distribution in GLV tokens to users impacted by the recent breach, along with a $500,000 reward fund to encourage retention of the allo...
Read Full Article →GMX finalizes $44M payout to GLP holders affected by V1 exploit
GMX has completed the distribution of approximately $44 million to liquidity providers on Arbitrum who experienced losses due to the security issue in the protocol's initial versio...
Read Full Article →Weight-loss drugs may be covered by Medicare, Medicaid under experimental program
The experimental program could potentially reduce out-of-pocket expenses for patients by allowing Medicare and Medicaid to cover expensive GLP-1 medications used for weight managem...
Read Full Article →Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agon...
The partnership grants exclusive rights to a novel oral treatment, potentially enhancing Madrigal Pharmaceuticals' revenue streams and expanding its product development portfolio i...
Read Full Article →Microdosing: how ‘off-label’ use of weight loss jabs is spreading from US to UK
The growing demand for lower-dose GLP-1 treatments in private healthcare settings indicates a potential shift in market dynamics, influencing pricing strategies and expanding reven...
Read Full Article →GMX hacker returns stolen funds after bounty negotiation
Following confidential discussions, the individual responsible for accessing GMX’s V1 GLP pool has begun reversing the financial impact by transferring the previously misappropriat...
Read Full Article →GMX Exploiter Return $40M Days After Hack, Token Zooms Higher
Following the recent breach involving manipulation of short positions, the perpetrators reimbursed $40 million, leading to a notable increase in the associated digital asset's mark...
Read Full Article →GMX token surges 14% after hacker begins returning funds from $40 million exploit
The partial recovery of stolen assets following the recent breach in GMX’s liquidity pool has influenced the token’s market value, reflecting investor reactions to the ongoing reso...
Read Full Article →Crypto hackers lift $42m from GMX’s Arbitrum liquidity pool in broad daylight
The recent exploit of GMX’s V1 liquidity pool resulted in a loss exceeding $40 million, raising concerns about the security of audited smart contracts and the stability of decentra...
Read Full Article →Hacker drains $42 million from decentralized perpetual exchange GMX
A cybercriminal successfully extracted a substantial amount of digital assets from GMX's liquidity pool, causing a significant monetary loss for the decentralized trading platform.
Read Full Article →The weight loss drug boom has barely begun. How big can it get?
The rising popularity of GLP-1 medications, including Ozempic, positions them to generate substantial revenue, potentially surpassing established blockbuster drugs like statins in...
Read Full Article →Slim pickings: grocery sales down as Brits turn to weight-loss jabs
The increasing adoption of prescription medications for weight management is contributing to reduced grocery store revenues, as consumers adjust their purchasing habits beyond typi...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →WeightWatchers scraps business model to team up with anti-obesity drugs provider
The collaboration with a pharmaceutical company offering GLP-1 treatments represents a strategic move for the brand to diversify revenue streams and address declining market compet...
Read Full Article →This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...
Read Full Article →Weight loss drugs are squeezing the food industry
The rapid success of GLP-1 medications is driving substantial revenue growth for pharmaceutical companies while simultaneously reducing consumer spending and demand within the food...
Read Full Article →Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom
WeightWatchers has filed for bankruptcy due to over $1 billion in debt, aiming to restructure its finances while shifting focus toward weight loss medications such as GLP-1 treatme...
Read Full Article →Weight loss drugs can help employers cut health care costs, study says
Employers may experience reduced healthcare expenses over time by investing in costly GLP-1 medications, as a comprehensive study of insurance claims indicates savings become appar...
Read Full Article →